CREATE Medicines raised a $122 million Series B to advance its in vivo CAR-T platform across autoimmune disease and oncology, pushing programs including CRT-402 (CD19 CAR T for autoimmune disease) and an oncology-directed asset targeting CD19 and BCMA combinations. The company said it has already dosed more than 50 patients across in vivo CAR clinical programs. The financing is co-led by existing investors and includes participation from Alexandria Venture Investments and others, with stated proceeds aimed at extending runway for clinical execution and internal manufacturing investment. CREATE emphasized repeat dosing potential and the ability to run “one-day manufacturing” via its mRNA-LNP approach delivering CAR instructions in the body. For the competitive landscape, the round underscores growing capital support for next-generation cellular therapies that seek to reduce logistical bottlenecks seen in conventional ex vivo CAR-T.